Comparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis
| dc.contributor.author | Gupta, Sana | |
| dc.contributor.author | Bell, Madison | |
| dc.contributor.author | Liu, Laurel | |
| dc.contributor.author | Xiong, Grace | |
| dc.contributor.author | Abu-Hilal, Mohannad | |
| dc.date.accessioned | 2026-11-17T04:31:06Z | |
| dc.date.issued | 2026-11-10 | |
| dc.date.updated | 2026-11-17T04:31:06Z | |
| dc.description.abstract | Abstract Introduction Despite the availability of several non-steroidal topical therapies for atopic dermatitis (AD), their comparative speed of clinical response remains unclear. This meta-analysis compared the efficacy of novel non-steroidal topical therapies for AD. Methods Four databases were searched for randomized controlled trials (RCTs) evaluating topical difamilast 1% twice daily (BID), tapinarof 1% once daily (QD), ruxolitinib 1.5% BID, roflumilast 0.05% or 0.15% QD in patients with AD. Outcomes included Investigator’s Global Assessment Treatment Success (IGA-TS) and 50%, 75% and 90% improvement in Eczema Area and Severity Index (EASI-50, EASI-75 and EASI-90) at weeks 1, 2, 4 and 8. Frequentist random-effects network meta-analyses estimated odds ratios (ORs) and 95% confidence intervals (CIs), primarily comprising indirect comparisons between non-steroidal topicals using a common vehicle comparator. Results Twenty-two RCTs (5843 participants) were included. Ruxolitinib demonstrated the highest odds of IGA-TS versus vehicle at week 2 (OR 8.94; 95% CI 5.28–15.12), 4 (OR 9.03; 95% CI 6.27–13.01) and 8 (OR 9.03; 95% CI 6.52–12.50), along with EASI-75 and EASI-90. Difamilast demonstrated favourable EASI-75 (OR 5.34; 95% CI 3.51–8.12) and EASI-90 (OR 6.71; 95% CI 3.79–11.89) responses versus vehicle at week 4; later data were unavailable. Conclusions Efficacy profiles varied across novel non-steroidal topical therapies, with ruxolitinib demonstrating the strongest and most consistent relative efficacy estimates. Response magnitude and timing remain important considerations when selecting topical AD treatments. | |
| dc.identifier.uri | https://doi.org/10.1007/s13555-026-01968-8 | |
| dc.identifier.uri | http://hdl.handle.net/10393/52239 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dc.title | Comparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis | |
| dc.type | Journal Article |
Fichiers
Trousse originale
1 - 1 sur 1
En cours de chargement...
- Nom:
- 13555_2026_Article_1968.pdf
- Taille:
- 1.92 MB
- Format:
- Adobe Portable Document Format
Trousse de licence
1 - 1 sur 1
En cours de chargement...
- Nom:
- license.txt
- Taille:
- 2.51 KB
- Format:
- Item-specific license agreed upon to submission
- Description:
